FebriDx® gains four new top 100 U.S. urgent care groups as rollout accelerates ahead of respiratory season
Lumos Diagnostics Holdings Ltd (ASX: LDX) has announced that four top 100 U.S. urgent care groups are now progressing simultaneously through its commercial pipeline, with two moving into active network rollout across more than 40 combined sites and two more advancing clinical and economic validation across more than 45 sites. Live sites have grown from 170 to 215, while sites under evaluation have expanded from 350 to 405. The update builds on ASX releases from 21 July 2026 and 27 July 2026, with all four accounts owned and operated by major U.S. health systems.
These developments come ahead of the respiratory illness season, a period of naturally elevated demand for point-of-care diagnostics such as FebriDx®. With 26 U.S. states now covered, >90% payment coverage at US$41.38 per test, and an estimated 0.9 million to 1.2 million acute respiratory illness (ARI) visits per annum across live sites, the pipeline reflects meaningful commercial depth.
When big ASX news breaks, our subscribers know first
The four-stage commercial framework: how FebriDx® moves from pilot to protocol
Lumos employs a four-stage commercial framework to track how priority accounts progress from initial identification through to scaled, protocol-driven use of FebriDx®. For investors, this framework provides a transparent and trackable way to assess pipeline health rather than relying on vague engagement language.
The four stages are:
- Qualified opportunities — priority accounts identified and engaged based on patient volume, payer mix, strategic fit and network scale.
- Evaluation Phase: Clinical and economic validation — targeted assessment of clinical performance, reimbursement, workflow and health-economic factors across one or more sites to support broader adoption decisions.
- Implementation Phase I: Network rollout — deployment across multiple sites within an account following successful validation.
- Implementation Phase II: Standardised adoption — FebriDx® becomes embedded in standing orders, triage protocols or routine clinical pathways, supporting repeat ordering and scaled utilisation.
The WellStreet Urgent Care relationship illustrates how this model works in practice. Following a successful initial pilot, that programme expanded to 44 sites and established a pathway for broader deployment across WellStreet’s network of more than 165 sites. This pilot-to-scale pathway is the repeatable model underpinning Lumos’ broader commercialisation strategy.
The WellStreet pilot expansion from a single site to 43 locations across three U.S. regions in April 2026 was the first real-world demonstration of the pilot-to-scale model, with WellStreet implementing a standing order protocol that offered FebriDx to every patient presenting with acute respiratory symptoms.
Health-system ownership of these urgent care groups is significant. Integrated health systems have the institutional authority to embed FebriDx® into clinical protocols across their networks, enabling faster decision-making and more durable adoption than decentralised operators.
| Phase | Sites | Est. ARI Visits p.a. | Key Milestone | Notes |
|---|---|---|---|---|
| Evaluation Phase: Clinical & Economic Validation | 405 | 1.6m–2.2m | Sites under active clinical & economic validation | Includes Top 10, 25 and 30 urgent care groups; 5 in Top 100 |
| Implementation Phase I: Network Rollout | 215 live sites across 26 states | 0.9m–1.2m | Deployment across multiple sites post-validation | Includes two new Top 100 urgent care groups; >90% payment coverage at US$41.38/test |
| Implementation Phase II: Standardised Adoption | FebriDx® embedded in triage protocols and standing orders |
What the four new accounts signal for Lumos’ top 100 strategy
The two accounts that have progressed into network rollout are described in the announcement as:
- A large, integrated regional health system with a broad network of hospital, outpatient and community care services, including extended-hours, walk-in urgent care centres.
- A leading academic medical centre and health system, operating convenient care, urgent care and advanced urgent care services, providing walk-in access and serving as an entry point into a broader specialist, imaging and hospital network.
The two accounts currently advancing clinical and economic validation are:
- A multi-state, faith-based and community-focused health system with urgent care services spanning several local markets, providing both in-person and virtual access for patients with minor illnesses and injuries.
- A large Pacific Northwest health system operating a consumer-oriented urgent care network with extended hours and seven-day access, treating common acute presentations including respiratory infections, influenza-like illness, sore throat and colds.
Validation activities across these organisations cover clinical performance, reimbursement, workflow integration and health-economic impact, all of which inform decisions on broader deployment. These are the gates that health-system-owned operators require before committing to scale, and progressing through them signals genuine institutional engagement with FebriDx®.
The strategic logic is significant. Top 100 urgent care groups represent an estimated 40% of all U.S. urgent care sites. Progress within these accounts is leveraged, not linear: a single network rollout decision can add dozens of sites simultaneously.
CEO, Doug Ward
“Securing two further top 100 urgent care groups, both backed by major U.S. health systems, is a clear signal that FebriDx® is earning a place in frontline respiratory care. These are sophisticated organisations that evaluate diagnostics on clinical utility, workflow fit and economics before committing sites, and they are now moving into rollout ahead of the respiratory season. Pleasingly, FebriDx® is now deployed across 215 live sites, including 44 WellStreet sites, with a further 405 sites in the evaluation stage.”
CEO, Doug Ward
“Just as importantly, they are following the same path we established with WellStreet – pilot, validate, then expand. The repeatability of this model provides us with a strong foundation for scaling our top 100 urgent care group strategy with confidence.”
Investment thesis: pipeline depth, repeatable model, and seasonal timing
Four top 100 urgent care groups progressing simultaneously, a proven pilot-to-scale pathway, >90% reimbursement coverage at US$41.38 per test, and a seasonal demand backdrop together constitute a substantive near-term pipeline for FebriDx®.
All U.S. FebriDx® sales flow through Lumos’ exclusive distribution partner, Phase Scientific, as disclosed to the ASX on 16 July 2025. Lumos recognises FebriDx® revenue when product is shipped from Lumos to Phase Scientific. Investors should note this structure when assessing the timing of revenue recognition relative to site-level deployment activity.
Lumos has also indicated it expects to expand its pipeline dashboard over time, allowing investors to better assess how individual priority accounts are evolving across each commercial phase. This signals a commitment to disclosure discipline as the pipeline matures.
No revenue figures or earnings forecasts were disclosed in this announcement. The forward-looking indicators, including the estimated 1.6 million to 2.2 million ARI visits per annum across evaluation-stage sites, represent the potential commercial opportunity as validation-stage accounts progress toward rollout decisions, not confirmed revenue.
For investors wanting to assess the commercial durability behind the pipeline figures, our detailed coverage of FebriDx reimbursement performance from May 2026 examines the claim success data in depth, including how average payouts relative to the Medicare benchmark translate into per-test economics across live sites.
Don’t Miss the Next ASX Healthcare Breakout
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Over 20,000 active subscribers are already getting the full picture the moment announcements hit. Click the “Free Alerts” button at Big News Blast to stay ahead of market-moving healthcare news.